References

milmed

Военная медицина

Military Medicine

2074-5044

Белорусский государственный медицинский университет

milmed-750

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Особенности лечения артериальной гипертензии в отдельных клинических ситуациях. Фокус на кардиоренальную протекцию

Features of treatment of arterial hypertension in specific clinical situations, focus on cardiorenainal protection (Part 2)

Рудой

А. С.

Rudoy

Бова

А. А.

Bova

A. A.

Ливенцева

М. М.

Livenceva

M. M.

Кафедра военно-полевой терапии военно-медицинского факультета в УО «Белорусский государственный медицинский университет»BelarusРНПЦ «Кардиология»Belarus

2019

25102026

048593

2026

Рудой А.С., Бова А.А., Ливенцева М.М.

Rudoy S., Bova A.A., Livenceva M.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://milmed.ejournal.by/jour/article/view/750

В обзоре представлены обновленные Рекомендации по обследованию и лечению пациентов с артериальной гипертензией, принятые в июне 2018 года на конгрессе Европейского общества по артериальной гипертензии, а затем в августе 2018 года на ежегодном конгрессе Европейского общества кардиологов. Особенный интерес представляют различные вопросы, посвященные особенностям лечения артериальной гипертензии в отдельных клинических ситуациях (в фокусе кардиоренальная протекция). Несмотря на крайне высокие уровни доказательств, в новой версии Рекомендаций, многие позиции представленного документа профессиональному сообществу представляются спорными.

The review presents updated Guidelines for the management of arterial hypertension, adopted at the congress of the European Society of Hypertension in June 2018, and then at the annual congress of the European Society of Cardiology in August 2018. Of particular interest are various questions about the features of the treatment of arterial hypertension in certain clinical situations situations (in focus cardiorenal protection). In the new version of the Recommendations, many of the positions presented in the document to the professional community are contradictory, despite the extremely high level of evidence.

артериальная гипертензияантигипертензивная терапияхроническая болезнь почекхолестеринишемическая болезнь сердцафибрилляция предсердийзаболевания периферических артерий

arterial hypertensionantihypertensive therapychronic kidney diseasecholesterolischemic heart diseaseatrial fibrillationperipheral arterial disease

References1

Vidal-Petiot, E., Ford, I., Greenlaw, N., Ferrari, R., Fox K. M., Tardif, J. C. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142–52. doi: 10.1016/S0140–6736(16)31326–5

Böhm, M., Schumacher, H., Teo, K. K, Lonn, E. M., Mahfoud, F, Mann, J. F. E. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085): 2226–37. doi: 10.1016/S0140–6736 (17)30754–7

Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers A., Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–967.

Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., Lisheng, L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–952.

Rapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., White, I. R., Caulfield, M. J., Deanfield, J. E., Smeeth, L., Williams, B., Hingorani, A., Hemingway, H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and agespecific associations in 1.25 million people. Lancet 2014; 383:1899–1911.

Bangalore, S., Qin J., Sloan, S., Murphy, S. A., Cannon, C. P. PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation2010;122:2142–2151.

Messerli, F. H., Mancia, G., Conti, C. R., Hewkin, A. C., Kupfer, S, Champion, A., Kolloch, R., Benetos, A., Pepine, C. J. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884–893.

Law, M. R., Morris, J. K., Wald, N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665

Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M. J., Kastelein, J. J. et al. Rosuvastatin to prevent vascular events in men and women with elevated C‑reactive protein. N Engl J Med. 2010;359 (21):2195–207. doi:10.1056/ NEJMoa0807646

Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L .et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. New England Journal of Medicine [Internet]. 2016;374(21):2021–31. doi: 10.1056/NEJMoa1600176

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H. et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39):2999–3058l. doi: 10.1093/eurheartj/ehw27

Аронов, Д. М., Арабидзе, Г. Г., Ахмеджанов, Н. М., Балахонова, Т. В., Барбараш, О. Л., Бойцов, С. А. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр. 2017. [Электронный ресурс] https://noatero.ru/ru/diagnostika-i‑korrekciya-narusheniy-lipidnogoobmenas‑celyu-profilaktiki-i‑lecheniya-ateroskleroza

Anderson, C. S., Heeley, E., Huang, Y., Wang, J., Stapf, C., Delcourt, C., Lindley, R., Robinson, T., Lavados, P., Neal, B., Hata, J., Arima, H., Parsons, M., Li, Y., Wang, J., Heritier, S., Li Q,. Woodward, M., Simes, R. J., Davis, S. M., Chalmers, J. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N. Engl J. Med 2013;368:2355–2365.

Qureshi, A. I., Palesch, Y. Y., Barsan, W. G., Hanley, D. F., Hsu, C. Y., Martin, R. L., Moy, C. S., Silbergleit, R., Steiner, T., Suarez, J. I., Toyoda, K., Wang, Y., Yamamoto, H., Yoon, B. W. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016;375:1033–1043.

Tsivgoulis, G., Katsanos, A. H., Butcher, K. S., Boviatsis, E., Triantafyllou, N., Rizos, I., Alexandrov, A. V. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 2014;83:1523–1529.

Wu, W., Huo, X., Zhao, X., Liao, X., Wang, C., Pan, Y,. Wang, Y., Wang, Y. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016; 11:e0144260.

Lee, M., Ovbiagele, B., Hong, K. S., Wu, Y. L., Lee, J. E., Rao, N. M., Feng, W., Saver, J. L. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke 2015;46:1883–1889.

Zhao, R., Liu ,F. D., Wang, S., Peng, J. L., Tao, X. X., Zheng, B., Zhang, Q. T., Yao, Q., Shen, X. L., Li, W. T., Zhao, Y., Liu, Y. S., Su, J. J., Shu, L., Zhang, M., Liu, J. R. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or longterm dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore) 2015;94:e896.

Jauch, E. C., Saver, J. L., Adams, H. P. Jr., Bruno, A., Connors, J. J., Demaerschalk, B. M., Khatri, P., McMullan, P. W. Jr., Qureshi, A. I., Rosenfield, K., Scott, P. A., Summers, D. R., Wang, D. Z., Wintermark, M., Yonas, H. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44: 870–947.

Sandset, E. C., Murray, G. D., Bath, P. M., Kjeldsen, S. E., Berge, E. Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Stroke 2012;43:2108–2114.

ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385:617–628.

Robinson, T. G., Potter, J. F., Ford, G. A., Bulpitt, C. J., Chernova, J., Jagger, C., James, M. A., Knight, J., Markus, H. S., Mistri, A. K., Poulter, N. R. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blindedendpoint trial. Lancet Neurol 2010;9:767–775.

Odden, M. C., McClure, L. A., Sawaya, B. P., White, C. L., Peralta, C. A., Field, T. S., Hart, R. G., Benavente, O. R., Pergola, P. E. Achieved blood pressure and outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 2016;67:63–69.

White, C. L., Szychowski, J. M., Pergola, P. E., Field, T. S., Talbert, R., Lau ,H., Peri, K., Benavente, O. R. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc 2015;63:722–729.

Dahlof, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

Collier, D. J., Poulter, N. R, Dahlof, B., Sever, P. S., Wedel, H., Buch, J., Caulfield, M. J. Impact of amlodipinebased therapy among older and younger patients in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583–591.

National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. www.nice.org.uk/guidance/CG127 (April 2018).

Сидоренко, Б. А., Преображенский, А. В., Сопаевенко, А. В., Иванова, Н. А., Стеценко, Т. М. Кандесартан – новый блокатор AT1-ангиотензиновых рецепторов: особенности фармакологии и опыт использования при артериальной гипертензии. – 2004. – № 1. – [Электронный ресурс]. – URL: medi.ru<ahref=http://medi.ru/doc/091605.htm>].

Emdin, C. A., Rothwell, P. M., Salimi-Khorshidi, G., Kiran, A., Conrad, N., Callender ,T., Mehta, Z., Pendlebury, S. T., Anderson, S. G., Mohseni, H., Woodward, M., Rahimi, K. Blood pressure and risk of vascular dementia: evidence from a primary care registry and a cohort study of transient ischemic attack and stroke. Stroke 2016;47:1429–1435.

Levi Marpillat, N., Macquin-Mavier, I., Tropeano, A. I., Bachoud-Levi, A. C., Maison, P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013;31:1073–1082.

Godin, O., Tzourio, C., Maillard, P., Mazoyer, B., Dufouil, C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation 2011;123:266–273.

Snyder H. M., Corriveau R. A., Craft S., Faber J. E., Greenberg S. M., Knopman D., Lamb B. T., Montine T. J., Nedergaard M., Schaffer C. B., Schneider J. A., Wellington C., Wilcock D. M., Zipfel G. J., Zlokovic B., Bain L. J., Bosetti F., Galis Z. S., Koroshetz W., Carrillo M. C. Vascular contributions to cognitive impairment and dementia including Alzheimer’s disease. Alzheimers Dement 2015;11:710–717.

Schmieder, R. E., Mann, J. F., Schumacher, H., Gao, P., Mancia, G., Weber, M. A., McQueen, M., Koon, T., Yusuf, S. ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011;22:1353–1364.

de Zeeuw, D., Remuzzi, G., Parving, H. H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch W. E., Brenner, B. M. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921–927.

Bakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlof, B., Pitt, B., Jamerson, K., Velazquez, E. J., Staikos-Byrne, L., Kelly, R. Y., Shi V., Chiang, Y. T., Weber, M. A. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173–1181.

Malhotra, R., Nguyen, H. A., Benavente, O., Mete, M., Howard, B. V., Mant, J., Odden, M. C., Peralta, C. A., Cheung, A. K., Nadkarni G. N., Coleman, R. L., Holman, R. R., Zanchetti, A., Peters, R., Beckett, N., Staessen, J. A., Ix, J. H. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med 2017;177:1498–1505.

Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–252.

Sim, J. J., Shi J., Kovesdy, C. P., Kalantar-Zadeh K., Jacobsen, S. J. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014;64:588–597.

Clase, C. M., Barzilay, J., Gao P., Smyth, A., Schmieder, R. E., Tobe, S., Teo, K. K., Yusuf, S., Mann, J. F. Acute change in glomerular filtration rate with inhibition of the reninangiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683–690.

Schmidt, M., Mansfield, K. E., Bhaskaran, K., Nitsch, D., Sørensen, H. T., Smeeth, L., Tomlinson, L. A. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 2017;356:j791.

Conen, D., Tedrow, U. B., Koplan, B. A., Glynn, R. J., Buring, J. E., Albert, C. M. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146–2152. .

Grundvold, I., Skretteberg, P. T., Liestol, K., Erikssen, G., Kjeldsen, S. E., Arnesen, H., Erikssen, J., Bodegard, J. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012;59:198–204

Disertori, M., Latini, R., Barlera, S., Franzosi, M. G., Staszewsky, L., Maggioni ,A. P., Lucci, D., Di. Pasquale, G., Tognoni, G. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606–1617

Goette, A., Schon, N., Kirchhof, P., Breithardt, G., Fetsch, T., Hausler, K. G., Klein, H. U., Steinbeck, G., Wegscheider, K., Meinertz, T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol2012; 5:43–51.

Fagard, R. H., Celis, H., Thijs, L., Wouters, S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084–1091.

McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P. Rizkala, A. R., Rouleau, J. L., Shi, V.C., Solomon, S. D., Swedberg, K., Zile, M. R. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.

The authors declare that there are no conflicts of interest present.